ENTO: מכפיל P/S עתידי Entero Therapeutics Inc.

Entero Therapeutics (ENTO) - לוגו תאגידי

The current forward P/S ratio illustrates the valuation dynamics of shares relative to future sales, where the level of represents the current value. The business is protected by the humanitarian status of medicine and operates within stable jurisdictions. A compact staff of scientists focuses on patents and clinical trials. Revenues for Entero Therapeutics, Inc. (ENTO) will be based on the commercialization of innovative drugs for the therapy of celiac disease.

ENTO Entero Therapeutics Inc.: מחיר עתידי (Forward) למכירות בטווח 04.07.2022 - 16.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Entero (ENTO)

ניתוח כללי של החברה:Entero Therapeutics ENTO
מוצרים מיוצרים של Entero Therapeutics Inc.

Since Entero Therapeutics, Inc. (ENTO) operates on external funding without stable operating revenues, the expected revenue multiple reflects the market rate for the success of future clinical trials. This indicator compares current market capitalization with projected turnover, allowing investors to assess the degree of asset overvaluation relative to potential financial results in the absence of current profits.